CPT® Code 91312

Deleted

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

The CPT® Code 91312 refers to the bivalent mRNA-LNP vaccine designed to provide immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the disease known as COVID-19. This vaccine is formulated with messenger RNA (mRNA) that encodes the spike protein of the virus, allowing the immune system to recognize and respond to the virus effectively. The vaccine is preservative-free and is delivered in a dosage of 30 mcg per 0.3 mL, specifically designed for intramuscular administration. The bivalent nature of this vaccine means it contains mRNA components from both the original strain of the virus and the omicron variant, which includes the BA.4 and BA.5 subvariant lineages. This dual-target approach enhances the immune response and provides broader protection against circulating strains of the virus. The lipid nanoparticles (LNP) encapsulating the mRNA facilitate the delivery of the genetic material into the body's cells, enabling them to produce the viral spike protein without the need for additional adjuvants to stimulate the immune response. Following vaccination, the immune system generates antibodies that can recognize and neutralize the virus upon exposure, thereby reducing the risk of severe illness. It is important to note that this code specifically reports the supply of the Pfizer-BioNTech bivalent booster vaccine for individuals aged 12 years and older who have previously received COVID-19 vaccinations. The TRIS-sucrose formulation includes buffering agents that help stabilize the vaccine and maintain its pH, ensuring its efficacy and safety during storage and administration.